Hugh Klein1, Thomas Alex Washington2. 1. Kensington Research Institute, Silver Spring, Maryland, United States of America. 2. California State University-Long Beach, Long Beach, California, United States of America.
Abstract
Despite being at the cornerstone of current initiatives to curtail the spread of HIV, Pre-Exposure Prophylaxis (PrEP) medication has been slow to proliferate among many "at risk" populations. This is true for men who have sex with other men (MSM), who account for the largest number of new HIV diagnoses in the United States. To try to understand why MSM are not adopting PrEP in greater numbers, the present authors have created a 22-item PrEP Stigma Scale. This paper reports findings for that scale. METHODS: Purposive sampling was used to derive a sample of 273 diverse MSM. Men completed a brief questionnaire inquiring about their awareness of PrEP, willingness to avail themselves of various sources of information about PrEP, perceptions about PrEP-related stigma, and perceptions about obstacles to PrEP use. Cronbach's alpha reliability coefficients were computed for the PrEP Stigma Scale, for the full sample and for key subgroups. Factor analysis was performed to determine whether or not subscales exist. RESULTS: The PrEP Stigma Scale was found to be highly reliable, both in its full version (alpha=0.96) and in its shortened version (alpha=0.95). Reliability estimates were strong for all subgroups based on age, race, sexual orientation, educational attainment, relationship status, and HIV serostatus. Two subscales were identified, each with excellent reliability (alpha=0.95 and 0.94), again for the sample as a whole and for all key subgroups. CONCLUSIONS: The PrEP Stigma Scale shows great promise for aiding our understanding of why more MSM are not adopting PrEP. It was found to be reliable for all key subgroups under examination, and that is true both for the 22-item and the 11-item version of the scale.
Despite being at the cornerstone of current initiatives to curtail the spread of HIV, Pre-Exposure Prophylaxis (PrEP) medication has been slow to proliferate among many "at risk" populations. This is true for men who have sex with other men (MSM), who account for the largest number of new HIV diagnoses in the United States. To try to understand why MSM are not adopting PrEP in greater numbers, the present authors have created a 22-item PrEP Stigma Scale. This paper reports findings for that scale. METHODS: Purposive sampling was used to derive a sample of 273 diverse MSM. Men completed a brief questionnaire inquiring about their awareness of PrEP, willingness to avail themselves of various sources of information about PrEP, perceptions about PrEP-related stigma, and perceptions about obstacles to PrEP use. Cronbach's alpha reliability coefficients were computed for the PrEP Stigma Scale, for the full sample and for key subgroups. Factor analysis was performed to determine whether or not subscales exist. RESULTS: The PrEP Stigma Scale was found to be highly reliable, both in its full version (alpha=0.96) and in its shortened version (alpha=0.95). Reliability estimates were strong for all subgroups based on age, race, sexual orientation, educational attainment, relationship status, and HIV serostatus. Two subscales were identified, each with excellent reliability (alpha=0.95 and 0.94), again for the sample as a whole and for all key subgroups. CONCLUSIONS: The PrEP Stigma Scale shows great promise for aiding our understanding of why more MSM are not adopting PrEP. It was found to be reliable for all key subgroups under examination, and that is true both for the 22-item and the 11-item version of the scale.
Entities:
Keywords:
Pre-Exposure Prophylaxis (PrEP); gay men; men who have sex with men (MSM); scale reliability; stigma
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Jeffrey T Parsons; H Jonathon Rendina; Jonathan M Lassiter; Thomas H F Whitfield; Tyrel J Starks; Christian Grov Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Ronald A Brooks; Raphael J Landovitz; Rotrease Regan; Sung-Jae Lee; Vincent C Allen Journal: Int J STD AIDS Date: 2015-01-30 Impact factor: 1.359
Authors: Matt G Mutchler; Bryce McDavitt; Mansur A Ghani; Kelsey Nogg; Terrell J A Winder; Juliana K Soto Journal: AIDS Patient Care STDS Date: 2015-06-29 Impact factor: 5.078
Authors: Sarah K Calabrese; Kristen Underhill; Valerie A Earnshaw; Nathan B Hansen; Trace S Kershaw; Manya Magnus; Douglas S Krakower; Kenneth H Mayer; Joseph R Betancourt; John F Dovidio Journal: AIDS Behav Date: 2016-07
Authors: Omar Martinez; Elwin Wu; Ethan C Levine; Miguel Muñoz-Laboy; M Isabel Fernandez; Sarah Bauerle Bass; Eva M Moya; Timothy Frasca; Silvia Chavez-Baray; Larry D Icard; Hugo Ovejero; Alex Carballo-Diéguez; Scott D Rhodes Journal: PLoS One Date: 2016-03-30 Impact factor: 3.240
Authors: R J Munthali; A L Stangl; D Baron; I Barré; S Harvey; L Ramskin; M Colombini; N Naicker; S Kapiga; S Delany-Moretlwe Journal: AIDS Behav Date: 2022-07-01
Authors: Henna Budhwani; İbrahim Yiğit; Allysha C Maragh-Bass; Crissi B Rainer; Kristina Claude; Kathryn E Muessig; Lisa B Hightow-Weidman Journal: AIDS Behav Date: 2022-08-27